bioAffinity Technologies (BIAFW) Liabilities and Shareholders Equity (2021 - 2026)

bioAffinity Technologies has disclosed Liabilities and Shareholders Equity across 6 years of filings, most recently posting $7.9 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 43.23% year-over-year to $7.9 million; the TTM figure through Mar 2026 stood at $35.2 million (up 39.31% YoY), while the FY2025 annual figure was $11.0 million, up 68.27% from the prior year.
• Liabilities and Shareholders Equity slipped to $7.9 million in Q1 2026, from $11.0 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for BIAFW reached as high as $14.1 million in Q3 2022 and fell as low as $4.8 million in Q2 2025.
• The 5-year median for Liabilities and Shareholders Equity is $8.2 million (2023), against an average of $8.8 million.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 738.23% — and 2024, when it slumped 35.7%.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $12.2 million in 2022, then slumped by 32.51% to $8.2 million in 2023, then dropped by 20.77% to $6.5 million in 2024, then surged by 68.27% to $11.0 million in 2025, then declined by 27.51% to $7.9 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $7.9 million, $11.0 million, and $11.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.